Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
Similar Posts
BsUFA IV: Fiscal Years 2028-2032
On September 30, 2022, the President signed into law the FDA User Fee Reauthorization Act of 2022.FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false and misleading claims regarding compounded GLP-1 products offered on their websites.System Correction: IMPRIS Imaging Inc Issues Correction for IMRIS Neuro III-SV
IMPRIS corrects IMRIS Neuro III-SV models due to the potential of ice blockage in the helium venting pipeAnesthetic Vaporizer Recall: Draeger Removes Vapor 2000 and Vapor 3000 Vaporizers
Draeger is removing certain Vapor 2000 and Vapor 3000 Vaporizers due to impurities found within a component.Ultra Seal Corporation – 624650 – 09/25/2024
CGMP/Finished Pharmaceuticals/AdulteratedGDUFA IV: Fiscal Years 2028 – 2032
Information related to FDA’s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.